CR9246A - Formulaciones terapeuticas del factor de crecimiento de queratinocitos - Google Patents

Formulaciones terapeuticas del factor de crecimiento de queratinocitos

Info

Publication number
CR9246A
CR9246A CR9246A CR9246A CR9246A CR 9246 A CR9246 A CR 9246A CR 9246 A CR9246 A CR 9246A CR 9246 A CR9246 A CR 9246A CR 9246 A CR9246 A CR 9246A
Authority
CR
Costa Rica
Prior art keywords
growth factor
keratinocit
therapeutic formulations
keratinocyte growth
lyophilized
Prior art date
Application number
CR9246A
Other languages
English (en)
Inventor
J Treuheit Michael
Dharmavaram Vasumathi
Purtell Judith
E Roy Suzanne
Original Assignee
Biovitrum Ab Publ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum Ab Publ filed Critical Biovitrum Ab Publ
Publication of CR9246A publication Critical patent/CR9246A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion provee formulaciones del factor de crecimiento de queratinocitos liofilizado, las cuales presentan estabilidad a lago plazo. Ademas, provee metodos para preparar una composicion liofilizada que incluye al factor de crecimiento de queratinocitos.
CR9246A 2004-12-15 2007-07-13 Formulaciones terapeuticas del factor de crecimiento de queratinocitos CR9246A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63621004P 2004-12-15 2004-12-15

Publications (1)

Publication Number Publication Date
CR9246A true CR9246A (es) 2007-10-23

Family

ID=36337531

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9246A CR9246A (es) 2004-12-15 2007-07-13 Formulaciones terapeuticas del factor de crecimiento de queratinocitos

Country Status (27)

Country Link
US (1) US8304387B2 (es)
EP (1) EP1827483B1 (es)
JP (1) JP5201992B2 (es)
KR (1) KR101283736B1 (es)
CN (1) CN101084008B (es)
AR (1) AR052339A1 (es)
AU (1) AU2005317166B2 (es)
BR (1) BRPI0519070A2 (es)
CA (1) CA2589889C (es)
CR (1) CR9246A (es)
DK (1) DK1827483T3 (es)
EA (1) EA013369B1 (es)
ES (1) ES2504441T3 (es)
HR (1) HRP20140926T1 (es)
IL (1) IL183435A (es)
MX (1) MX2007006822A (es)
MY (1) MY145638A (es)
NO (1) NO20073629L (es)
NZ (1) NZ555503A (es)
PL (1) PL1827483T3 (es)
PT (1) PT1827483E (es)
RS (1) RS53548B1 (es)
SI (1) SI1827483T1 (es)
TW (1) TWI351966B (es)
UA (1) UA88497C2 (es)
WO (1) WO2006065861A2 (es)
ZA (1) ZA200706095B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2589889C (en) 2004-12-15 2013-07-30 Amgen Inc. Therapeutic formulations of keratinocyte growth factor
US20090186805A1 (en) * 2006-07-06 2009-07-23 Aaron Thomas Tabor Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
KR100784134B1 (ko) * 2006-10-09 2007-12-12 주식회사 대웅 상피세포성장인자를 함유하는 안정한 구내염 치료용 액상조성물
CN107041948A (zh) * 2009-01-21 2017-08-15 北京三有利科技发展有限公司 细胞生长因子治疗溃疡性疾病和肺纤维化疾病的应用
IT1396020B1 (it) * 2009-10-16 2012-11-09 Fitologica Srl Composizione topica a base di biopeptidi, e suo utilizzo in campo tricologico.
CN102675449B (zh) * 2011-03-17 2016-06-08 重庆富进生物医药有限公司 缺失型人角质细胞生长因子-ⅰ二硫键变构体及其用途
EP2773364A1 (en) * 2011-11-02 2014-09-10 The University of Chicago Stable pharmaceutical formulations of growth factor peptides
CN102379838B (zh) * 2011-11-02 2013-06-12 广州舒泰生物技术有限公司 一种舒缓静颜化妆品的制备方法及应用
US20150126433A1 (en) * 2012-04-25 2015-05-07 University Of Cincinnati Growth factors for the treatment of mycobacterial infection
TWI828269B (zh) 2013-03-15 2024-01-01 美商百歐維拉提夫治療公司 因子ix多肽調配物
SG11201607642RA (en) 2014-03-24 2016-10-28 Biogen Ma Inc Lyophilized factor ix formulations
CN108359634A (zh) * 2018-02-02 2018-08-03 江阴司特易生物技术有限公司 一种饲养细胞蛋白复合物及其应用
CN109402130A (zh) * 2018-11-23 2019-03-01 成都中医药大学附属医院 一种重组人角质细胞生长因子-1及其制备方法和用途
PH12021552944A1 (en) * 2019-06-24 2022-07-25 Hangzhou Dac Biotech Co Ltd A formulation of a conjugate of a tubulysin analog to a cell-binding molecule
CN110339345B (zh) * 2019-07-30 2022-11-29 重庆派金生物科技有限公司 一种重组人截短型角质细胞生长因子-1滴眼液及其制备方法和应用
EP4183796A1 (en) 2021-11-19 2023-05-24 Enantis s.r.o. Thermostable fgf10 polypeptide or fragment thereof use thereof
CN119632934A (zh) * 2025-02-19 2025-03-18 杭州熙岭生物科技有限公司 一种kgf-2组合物的冻干粉及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026291B1 (en) 1989-01-31 2006-04-11 The United States Of America As Represented By The Department Of Health And Human Services Epithelial cell specific growth factor, keratinocyte growth factor (KGF)
GEP20022681B (en) 1989-01-31 2002-04-25 Aaronson Us Stuart A Protein KFG, Antibodies, Pharmaceutical Composition, Their Use, recombinant DNA, Cell, Method for Discoveries and Production of Proteins, Method for Stimulation of Epithelial Cells Growth
SK279641B6 (sk) * 1991-12-20 1999-01-11 Novo Nordisk A/S Stabilizovaný farmaceutický prípravok obsahujúci r
US7084119B2 (en) 1993-06-29 2006-08-01 Chiron Corporation Truncated keratinocyte growth factor (KGF) having increased biological activity
BR9407035A (pt) 1993-06-29 1996-03-12 Chiron Corp Fragmento de fator de crescimento de queratinócitos conjugado composição terapêutica molécula de DNA vetor de expressão célula hospedeira processo para produzir fragmento de fator de crescimento de queratinócitos processo para cicatrização de ferimento e processo de tratamento de doença hiperproliferativa da epiderme
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
CN1168678A (zh) 1994-10-13 1997-12-24 安姆根有限公司 用kgf治疗糖尿病的方法
MX9702665A (es) 1994-10-13 1997-07-31 Amgen Inc Analogos del factor de crecimiento de queratinocitos.
US6008328A (en) 1994-10-13 1999-12-28 Amgen Inc. Method for purifying keratinocyte growth factors
US6790439B1 (en) * 1995-06-07 2004-09-14 Zymogenetics, Inc. Thrombopoietin compositions
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
DK1012186T3 (da) 1996-12-06 2002-11-04 Amgen Inc Keratinocyt-vækstfaktorer og anvendelser deraf
US20020012961A1 (en) * 1999-04-15 2002-01-31 Genentech, Inc. Fibroblast growth factor- 19
KR20010033484A (ko) * 1997-12-22 2001-04-25 휴먼 게놈 사이언시즈, 인크. 각질세포 성장 인자-2 제제
KR20020010920A (ko) * 1999-06-02 2002-02-06 추후제출 각질세포 성장 인자-2 제제
US6440414B1 (en) * 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
CA2589889C (en) 2004-12-15 2013-07-30 Amgen Inc. Therapeutic formulations of keratinocyte growth factor

Also Published As

Publication number Publication date
TW200635603A (en) 2006-10-16
NO20073629L (no) 2007-09-10
JP5201992B2 (ja) 2013-06-05
HK1115298A1 (en) 2008-11-28
ES2504441T3 (es) 2014-10-08
CN101084008A (zh) 2007-12-05
AR052339A1 (es) 2007-03-14
HRP20140926T1 (hr) 2014-11-07
ZA200706095B (en) 2008-09-25
AU2005317166A1 (en) 2006-06-22
US20060128622A1 (en) 2006-06-15
US8304387B2 (en) 2012-11-06
BRPI0519070A2 (pt) 2008-12-23
MX2007006822A (es) 2007-07-24
CN101084008B (zh) 2013-04-10
MY145638A (en) 2012-03-15
AU2005317166B2 (en) 2009-09-10
EP1827483B1 (en) 2014-07-02
KR101283736B1 (ko) 2013-07-08
WO2006065861A3 (en) 2006-08-17
SI1827483T1 (sl) 2014-11-28
IL183435A0 (en) 2007-09-20
JP2008524229A (ja) 2008-07-10
CA2589889A1 (en) 2006-06-22
KR20070093977A (ko) 2007-09-19
TWI351966B (en) 2011-11-11
PT1827483E (pt) 2014-09-25
EA200701293A1 (ru) 2008-02-28
RS53548B1 (sr) 2015-02-27
UA88497C2 (ru) 2009-10-26
PL1827483T3 (pl) 2014-12-31
DK1827483T3 (da) 2014-10-06
EA013369B1 (ru) 2010-04-30
NZ555503A (en) 2010-01-29
WO2006065861A2 (en) 2006-06-22
CA2589889C (en) 2013-07-30
IL183435A (en) 2010-11-30
EP1827483A2 (en) 2007-09-05

Similar Documents

Publication Publication Date Title
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
CY1122681T1 (el) Απο του στοματος σκευασματα αναλογων κυτιδινης και μεθοδοι χρησης αυτων
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
HN2008000311A (es) Formas cristalinas de 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida
UY30302A1 (es) Formulaciones de pepticuerpos terapeuticos liofilizados
CR10528A (es) Proceso para producir poxvirus y composiciones de poxvirus
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
GT200600316A (es) Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
CR9558A (es) Formulaciones de quinina
AR066042A1 (es) Moleculas y metodos para modular la proteina convertasa-subtilisina /quexina tipo 9 (pcsk9)
CR8207A (es) Un conjugado citotoxico ca6 antigeno- especifico y metodos para utilizar el mismo
CR11580A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf
CR10290A (es) Metodos para reducir la aglomeracion de proteina
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
PA8660301A1 (es) Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricacion y utilizacion
PA8650801A1 (es) Composiciones y formulaciones de ecteinascidina, como la ecteinascidina 743
AR064614A1 (es) Producto combinado par controlar parasitos en animales
UY31484A1 (es) Piperidinas heteroaril-sustituidas
HN2008001393A (es) Derivados de 1,2,4,5- tetrahidro -3h- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
CR10304A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
NO20073629L (no) Terapeutiske formuleringer av keratinocyttvekstfaktor
CY1117237T1 (el) Συνθεσεις σταθερων τιακουμυκινων
AR054937A1 (es) Goma de mascar biodegradable
CR11406A (es) Conjugados de neurturina novedosos para uso farmaceutico
ATE503491T1 (de) Verbesserte anthraximpfstoffe und abgabeverfahren